文献速递临床试验与 GCP

甲磺酸萘莫司他治疗COVID-19肺炎患者的疗效:随机对照试验研究方案

Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-11-23

该研究为在韩国开展的随机、开放、多中心、两组临床试验,计划纳入84例COVID-19肺炎患者,随机分为干预组(标准治疗联合甲磺酸萘莫司他0.1至0.2 mg/kg/h,即2.4至4.8 mg/kg/day)和对照组(仅标准治疗),主要结局为临床改善比例,即存活出院或七分类临床状态量表下降2个类别。

要点

  • 干预组在标准治疗基础上加用甲磺酸萘莫司他0.1至0.2 mg/kg/h(2.4至4.8 mg/kg/day)。
  • 主要结局为存活出院或七分类量表下降2类的患者比例。
  • 次要结局包括国家早期预警评分变化、住院时长、28天死亡率及不良事件等。

核心结论

  • 该研究旨在评估甲磺酸萘莫司他联合标准治疗能否改善COVID-19肺炎患者的严重程度和死亡率。

研究设计与样本

  • 在韩国开展的随机、开放、多中心、两组临床试验,计划纳入84例COVID-19肺炎患者,随机分配至干预组或对照组。

主要发现

  • 干预组接受标准治疗联合甲磺酸萘莫司他,剂量为0.1至0.2 mg/kg/h(2.4至4.8 mg/kg/day)。
  • 对照组接受标准治疗,包括洛匹那韦/利托那韦、羟氯喹、氧疗、无创和有创呼吸机、抗生素治疗、肾脏替代治疗及体外膜肺氧合(ECMO)。
  • 主要结局为临床改善比例,定义为存活出院或七分类临床状态量表下降2个类别。
  • 次要结局包括国家早期预警评分变化、住院时长、新发无创通气或高流量氧疗或呼吸机使用发生率、28天死亡率、病毒载量变化及不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study is designed to evaluate the main hypothesis that nafamostat mesilate with standard therapy improves the severity and mortality rate in patients with COVID-19 pneumonia. METHODS: We conduct a randomized, open type, multi-institute/center, 2-group clinical trial with COVID-19 pneumonia patients in Korea. Eighty four patients with COVID-19 pneumonia are randomly assigned to intervention group or control group. Patients in intervention group receive the standard therapy with a dose of 0.1 to 0.2 mg/kg/h (2.4 to 4.8 mg/kg/day) of nafamostat mesilate. Patients in control group receive the standard therapy such as lopinavir/ritonavir, hydroxychloroquine, oxygen therapy, non-invasive and invasive ventilator, antibiotic therapy, renal-replacement therapy, and extracorporeal membrane oxygenation (ECMO). The primary outcome is proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status, as well as secondary outcome comprised change in National Early Warning Score, duration of hospitalization, incidence of new-non-invasive ventilation or high flow oxygen use or ventilator, mortality at day 28, viral load change, and adverse events. DISCUSSION: Our study contributes to the establishment of therapeutic strategy in COVID-19 pneumonia by evaluating the therapeutic effect and safety of nafamostat mesilate. TRIAL REGISTRATION: ClinicalTrials.gov NCT04418128. Registered on 5 June 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Moon K, Hong KW, Bae IG, et al. Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34814935. doi:10.1186/s13063-021-05760-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。